RVMD — Revolution Medicines Cashflow Statement
0.000.00%
Last trade - 00:00- $10.11bn
- $7.98bn
- 39
- 19
- 53
- 28
Annual cashflow statement for Revolution Medicines, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -108 | -187 | -249 | -436 | -600 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 12.7 | 27 | 32.8 | 42.9 | 34.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -7.93 | 8.72 | -13.1 | 40.7 | 1.17 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -100 | -147 | -224 | -351 | -557 |
| Capital Expenditures | -2.93 | -6.53 | -10.8 | -7.73 | -10.3 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -231 | -136 | -13.3 | -335 | -544 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -234 | -142 | -24.1 | -343 | -554 |
| Financing Cash Flow Items | 0 | -0.424 | 0.042 | 837 | 0.284 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 423 | 294 | 301 | 1,229 | 959 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 88.5 | 4.88 | 52.9 | 536 | -152 |